EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8

Elias A T Koch iD, Renato Liguori iD, Alejandro Afonso Castro, Stefan Schliep, Anne Petzold, Anja Wessely, Waltraud Fröhlich, Fulvia Ferrazzi iD, Julio Vera iD, Markus Eckstein, Carola Berking iD, Markus V Heppt iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26209964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Elias A T Koch und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Fri…. Hauptthemen laut MEDLINE: Melanoma, Uveal Neoplasms, Immune Checkpoint Inhibitors, CD28 Antigens. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hiege Foundation, Deutsche Forschungsgemeinschaft, German Ministry of Education and Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients with metastatic uveal melanoma (UM), tebentafusp is currently the only systemic therapy approved by the EMA and FDA, but its use is limited to HLA-A*02:01-positive individuals. Immune checkpoint blockade (ICB) represents another option, though only a small subgroup of patients benefits, and no reliable predictive biomarkers are available to date. The aim of this study was therefore to identify parameters associated with favorable ICB response. Tumor samples and clinical data from 30 patients were analyzed. Group A (n = 16) showed clinical benefit, while Group B (n = 14) experienced disease progression. NanoString® analyses revealed 258 upregulated genes in Group A, including IDO1, CD28, and CCL8. The enriched pathways were predominantly linked to immune activation, leukocyte adhesion, and responses to external stimuli. Immunohistochemistry confirmed significantly higher CD28 expression on infiltrating immune cells in Group A, while a machine learning approach identified CCL8 as a predictive marker with ~78% accuracy. Overall survival differed significantly between the groups. These findings indicate that patients responding to ICB display tumors with enhanced immune activation. CD28 and CCL8 emerged as promising candidates and should be validated in prospective studies to determine their clinical utility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaUveal NeoplasmsImmune Checkpoint InhibitorsCD28 AntigensHumansUveal MelanomaMaleMiddle AgedFemaleAgedBiomarkers, TumorAdultGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

CCL8CD28biomarkersimmune checkpoint blockadeuveal melanoma

Substanzen

Immune Checkpoint InhibitorsCD28 AntigensBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Dermatology, Deutsches Zentrum Immuntherapie (DZI), CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen,…
  • Institute of Pathology, CCC Erlangen-EMN, Bavarian Cancer Research Center (BZKF), Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 91054 Erlangen, Germany.
  • Department of Nephropathology, Institute of Pathology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg, 91054 Erlangen, Germany.
  • Dermpath München, Laboratory for Dermatopathology, Oral Pathology, and Molecular Pathology, 80335 Munich, Germany.

ORCID-Profile: Elias A T Koch, Renato Liguori, Fulvia Ferrazzi, Julio Vera, Carola Berking, Markus V Heppt

Förderung

  • Hiege Foundation
  • Deutsche Forschungsgemeinschaft
  • German Ministry of Education and Research
  • Friedrich Mahron Foundation

Zitieren

APA

Koch, E. A. T., Liguori, R., Castro, A. A., Schliep, S., Petzold, A., Wessely, A., Fröhlich, W., Ferrazzi, F., Vera, J., Eckstein, M., Berking, C., & Heppt, M. V. (2025). Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26209964

Vancouver

Koch EAT, Liguori R, Castro AA, Schliep S, Petzold A, Wessely A, et al. Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26209964

BibTeX
@article{Koch2025,
  author = {Koch, Elias A T and Liguori, Renato and Castro, Alejandro Afonso and Schliep, Stefan and Petzold, Anne and Wessely, Anja and Fröhlich, Waltraud and Ferrazzi, Fulvia and Vera, Julio and Eckstein, Markus and Berking, Carola and Heppt, Markus V},
  title = {Checkpoint Blockade Efficacy in Uveal Melanoma Is Linked to Tumor Immunity, CD28, and CCL8},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26209964}
}
Kostenlos starten →